

James F O'mahony

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8815592/publications.pdf>

Version: 2024-02-01

39
papers

514
citations

686830

13
h-index

676716

22
g-index

41
all docs

41
docs citations

41
times ranked

1029
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness evidence on approved cancer drugs in Ireland: the limits of data availability and implications for public accountability. <i>European Journal of Health Economics</i> , 2022, 23, 375-431.	1.4	1
2	Colorectal Cancer Screening within Colonoscopy Capacity Constraints: Can FIT-Based Programs Save More Lives by Trading off More Sensitive Test Cutoffs against Longer Screening Intervals?. <i>MDM Policy and Practice</i> , 2022, 7, 238146832210970.	0.5	3
3	NICE's Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests. <i>Pharmacoeconomics</i> , 2021, 39, 139-146.	1.7	1
4	Cervical screening during the COVID-19 pandemic: optimising recovery strategies. <i>Lancet Public Health</i> , The, 2021, 6, e522-e527.	4.7	37
5	Comment on Keeney et al.'s "Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening". <i>Pharmacoeconomics</i> , 2021, 39, 965-967.	1.7	1
6	Revision of Ireland's Cost-Effectiveness Threshold: New State-Industry Drug Pricing Deal Should Adequately Reflect Opportunity Costs. <i>Pharmacoeconomics - Open</i> , 2021, 5, 339-348.	0.9	3
7	Risk Stratification in Cost-Effectiveness Analyses of Cancer Screening: Intervention Eligibility, Strategy Choice, and Optimality. <i>Medical Decision Making</i> , 2021, , 0272989X2110509.	1.2	4
8	Does Cost-Effectiveness Analysis Really Need to Abandon the Incremental Cost-Effectiveness Ratio to Embrace Net Benefit?. <i>Pharmacoeconomics</i> , 2020, 38, 777-779.	1.7	5
9	Adherence to Discounting Guidelines: Evidence from Over 2000 Published Cost-Effectiveness Analyses. <i>Pharmacoeconomics</i> , 2020, 38, 809-818.	1.7	3
10	Interpreting cost-effectiveness ratios in a cost-effectiveness analysis of risk-tailored prostate screening: A critique of Callender et al.. <i>HRB Open Research</i> , 2020, 3, 23.	0.3	1
11	HIQA's Perspective on the Challenges Posed by Evaluations of Screening Programs: A Reply. <i>Value in Health</i> , 2019, 22, 136-138.	0.1	1
12	Unacceptable variation in screening colonoscopy. <i>BMJ: British Medical Journal</i> , 2019, 367, l6384.	2.4	2
13	The Joint Committee on Vaccination and Immunisation's Advice on Extending Human Papillomavirus Vaccination to Boys: Were Cost-Effectiveness Analysis Guidelines Bent to Achieve a Politically Acceptable Decision?. <i>Value in Health</i> , 2019, 22, 1227-1230.	0.1	5
14	Appraising the cost-effectiveness of vaccines in the UK: Insights from the Department of Health Consultation on the revision of methods guidelines. <i>Vaccine</i> , 2019, 37, 2831-2837.	1.7	4
15	Beneluxa: What are the Prospects for Collective Bargaining on Pharmaceutical Prices Given Diverse Health Technology Assessment Processes?. <i>Pharmacoeconomics</i> , 2019, 37, 627-630.	1.7	11
16	Preeclampsia Prevention Using Routine Versus Screening Test-Indicated Aspirin in Low-Risk Women. <i>Hypertension</i> , 2018, 72, 1391-1396.	1.3	29
17	Surveying the Cost-Effectiveness of the 20 Procedures with the Largest Public Health Services Waiting Lists in Ireland: Implications for Ireland's Cost-Effectiveness Threshold. <i>Value in Health</i> , 2018, 21, 897-904.	0.1	13
18	Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine. <i>Pharmacoeconomics</i> , 2017, 35, 5-13.	1.7	22

#	ARTICLE	IF	CITATIONS
19	Evaluation of the Effectiveness and Cost-Effectiveness of Personalized Surveillance After Colorectal Adenomatous Polypectomy. <i>Epidemiologic Reviews</i> , 2017, 39, 148-160.	1.3	24
20	Systematic Review of Costs and Effects of Self-Management Interventions for Chronic Musculoskeletal Pain: Spotlight on Analytic Perspective and Outcomes Assessment. <i>Physical Therapy</i> , 2017, 97, 998-1019.	1.1	10
21	Cost-effectiveness estimates: the need for complete reporting. <i>Lancet Public Health</i> , The, 2017, 2, e211.	4.7	0
22	Health-related quality of life as measured by the EQ-5D in the prevention, screening and management of cervical disease: A systematic review. <i>Quality of Life Research</i> , 2017, 26, 2885-2897.	1.5	7
23	Determinants of Change in the Cost-effectiveness Threshold. <i>Medical Decision Making</i> , 2017, 37, 264-276.	1.2	38
24	Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations. <i>Pharmacoeconomics</i> , 2017, 35, 65-82.	1.7	24
25	Expanding the benefits of HPV vaccination to boys and men. <i>Lancet</i> , The, 2016, 388, 2992.	6.3	5
26	The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland's Health System?. <i>Pharmacoeconomics</i> , 2016, 34, 5-11.	1.7	34
27	Beware of Kinked Frontiers: A Systematic Review of the Choice of Comparator Strategies in Cost-Effectiveness Analyses of Human Papillomavirus Testing in Cervical Screening. <i>Value in Health</i> , 2015, 18, 1138-1151.	0.1	17
28	Assessing cost-effectiveness of HPV vaccines with decision analytic models: what are the distinct challenges of low- and middle-income countries? A protocol for a systematic review. <i>Systematic Reviews</i> , 2015, 4, 68.	2.5	4
29	HIQA's CEA of Breast Screening: Pragmatic Policy Recommendations are Welcome, but ACERs Reported as ICERs are Not. <i>Value in Health</i> , 2015, 18, 941-945.	0.1	7
30	Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice. <i>Pharmacoeconomics</i> , 2015, 33, 1255-1268.	1.7	56
31	The Influence of Disease Risk on the Optimal Time Interval between Screens for the Early Detection of Cancer. <i>Medical Decision Making</i> , 2015, 35, 183-195.	1.2	10
32	Objectivity and Equity: Clarity Required. A Response to Hill and Olson. <i>Pharmacoeconomics</i> , 2014, 32, 1249-1250.	1.7	1
33	Some Inconsistencies in NICE's Consideration of Social Values. <i>Pharmacoeconomics</i> , 2014, 32, 1043-1053.	1.7	43
34	NICE's Selective Application of Differential Discounting: Ambiguous, Inconsistent, and Unjustified. <i>Value in Health</i> , 2014, 17, 493-496.	0.1	34
35	Multicohort Models in Cost-Effectiveness Analysis. <i>Medical Decision Making</i> , 2013, 33, 407-414.	1.2	17
36	A Mathematical Approach for Evaluating Markov Models in Continuous Time without Discrete-Event Simulation. <i>Medical Decision Making</i> , 2013, 33, 767-779.	1.2	15

#	ARTICLE	IF	CITATIONS
37	Re: Cost-effectiveness of pertussis booster vaccination in the Netherlands. <i>Vaccine</i> , 2012, 30, 7141.	1.7	1
38	Practical Implications of Differential Discounting in Cost-Effectiveness Analyses with Varying Numbers of Cohorts. <i>Value in Health</i> , 2011, 14, 438-442.	0.1	21
39	Interpreting cost-effectiveness ratios in a cost-effectiveness analysis of risk-tailored prostate screening: A critique of Callender et al.. <i>HRB Open Research</i> , 0, 3, 23.	0.3	0